Filing Signals

Source: SEC EDGAR Compiled 2026-11-13 17:17 UTC 23 automated checks passing

← All events

Summit Therapeutics Inc.

CIK 1599298 SMMT·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. SEC comment letter UPLOAD
  2. Going concern 10-Q +14d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Going concern Filing comparison

Summit Therapeutics Inc. no longer reports substantial doubt about going concern

Substantial doubt about ability to continue as a going concern → No substantial-doubt conclusion identified

Evidence
Blank check
No
Comparable
Yes
Current state
none
Current state label
No substantial-doubt conclusion identified
Direction
eased
Prior filed
2026-07-23
Prior form
10-Q
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

SEC comment letter SEC correspondence

SEC staff questioned Summit Therapeutics Inc.'s accounting for MD&A

Letter dated 2026-04-02; published on EDGAR 2026-10-21 — the SEC releases comment letters only after the review closes.

We note these collaborations were entered into prior to the filing of your Form 10-K and are highlighted in your fourth quarter of 2025 earnings release, earnings call and accompanying slides/presentation. Management’s Discussion and Analysis of Financial Condition and Results of Operations, page 70 Results of Operations, page 73 Your research and development (R&D) expenses increased more then 220% during 2025 and…
Evidence
Direction
staff to company
Letter dated
2026-04-02
Published on edgar
2026-10-21
Reviewing
Summit Therapeutics Inc. Form 10-K for the fiscal year ended December 31, 2025 Filed February 23, 2026 File No. 001-36866 Dear Manmeet Soni: We have limited our
Source
SEC staff comment letter (UPLOAD)
Topics
MD&A
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗